Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 211 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pain, Migraine Clear all
Completed Not applicable Interventional

Migraine--Investigational Treatment of Migraine With Noninvasive Brain Stimulation. (tDCS- Migraine)

NCT00521196
View directory record Official record
Conditions
Migraine
Interventions
DC Stimulator (Transcranial Direct Current Stimulator)
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Jul 22, 2026, 2:13 PM EDT
Completed No phase listed Observational Results available

The Utility of Telemedicine in the Management of Migraine

NCT01706003
View directory record Official record
Conditions
Migraine Headaches
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2019 · Synced Jul 22, 2026, 2:13 PM EDT
Completed Phase 3 Interventional Results available

A Study of Lasmiditan (LY573144) Over Four Migraine Attacks

NCT03670810
View directory record Official record
Conditions
Migraine
Interventions
Lasmiditan, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,633 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
14
States / cities
Huntsville, Alabama • Phoenix, Arizona • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Jul 22, 2026, 2:13 PM EDT
Completed No phase listed Observational

Real-world Data Analysis of REN Treatment in Migraine Patients

NCT04992897
View directory record Official record
Conditions
Migraine
Interventions
Remote Electrical Neuromodulation (REN)
Device
Lead sponsor
Theranica
Industry
Eligibility
Not listed
Enrollment
12,151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Jul 22, 2026, 2:13 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine

NCT05679908
View directory record Official record
Conditions
Chronic Migraine, Chronic Migraine, Headache, Chronic Migraine Without Aura, Aura Migraine
Interventions
TNX-1900, Placebo Nasal Spray
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
26
States / cities
Little Rock, Arkansas • Lemon Grove, California • Oceanside, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Jul 22, 2026, 2:13 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use

NCT05509400
View directory record Official record
Conditions
Migraine
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
23
States / cities
Los Angeles, California • Stamford, Connecticut • Lake City, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 22, 2026, 2:13 PM EDT
Completed Phase 2 Interventional

A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

NCT06323928
View directory record Official record
Conditions
Migraine
Interventions
Lu AG09222, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
874 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
28
States / cities
Hoover, Alabama • Carlsbad, California • Fullerton, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 22, 2026, 2:13 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

NCT04616326
View directory record Official record
Conditions
Chronic Migraine
Interventions
Galcanezumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years to 17 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
45
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jul 22, 2026, 2:13 PM EDT
Completed Phase 4 Interventional Results available

Ticagrelor Therapy for RefrACTORy Migraine Study

NCT02518464
View directory record Official record
Conditions
Migraine, Headache, Migraine Headache
Interventions
Ticagrelor 90 mg twice per day
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Jul 22, 2026, 2:13 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

NCT01952574
View directory record Official record
Conditions
Migraine
Interventions
Erenumab, Placebo, Erenumab PFS, Erenumab AI/Pen
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
41
States / cities
Phoenix, Arizona • Long Beach, California • National City, California + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2022 · Synced Jul 22, 2026, 2:13 PM EDT
Terminated Phase 2 Interventional Results available

Melatonin for Adolescent Migraine Prevention Study

NCT03150797
View directory record Official record
Conditions
Migraine
Interventions
Melatonin, Placebo oral capsule
Drug
Lead sponsor
Amy Gelfand
Other
Eligibility
10 Years to 17 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Jul 22, 2026, 2:13 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Intranasal Lidocaine to Treat Pediatric Migraine in the Emergency Department

NCT03576820
View directory record Official record
Conditions
Migraine
Interventions
Lidocaine, Placebo
Drug
Lead sponsor
New York City Health and Hospitals Corporation
Other
Eligibility
10 Years to 20 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Jul 22, 2026, 2:13 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Osteopathic Manipulative Techniques for the Treatment of Chronic Migraine Headaches

NCT04520425
View directory record Official record
Conditions
Chronic Migraine, Headache
Interventions
Osteopathic manipulative therapy
Procedure
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Jul 22, 2026, 2:13 PM EDT
Completed No phase listed Observational Results available

A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines

NCT01749410
View directory record Official record
Conditions
Chronic Migraine, Headaches
Interventions
onabotulinumtoxinA
Biological
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2015 · Synced Jul 22, 2026, 2:13 PM EDT
Completed Phase 1Phase 2 Interventional

Occipital Nerve Stimulation to Treat Chronic Headaches

NCT00205894
View directory record Official record
Conditions
Headache Disorders
Interventions
bion microstimulator
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Scottsdale, Arizona • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 4, 2008 · Synced Jul 22, 2026, 2:13 PM EDT
Completed Not applicable Interventional

Zolmitriptan Nasal Spray Versus Eletriptan in the Acute Treatment of Migraine

NCT01276977
View directory record Official record
Conditions
Acute Migraine, Migraine Headache, Headache Disorders
Interventions
Zolmitriptan 5 mg Nasal Spray, Eletriptan 40 mg tablet
Drug
Lead sponsor
California Medical Clinic for Headache
Other
Eligibility
15 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2011 · Synced Jul 22, 2026, 2:13 PM EDT
Not listed Phase 2 Interventional

Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea

NCT04091789
View directory record Official record
Conditions
Dysmenorrhea, Headache, Migraine, Fatigue, Nausea, Mood Disturbance
Interventions
Pure Femme Tablets
Drug
Lead sponsor
Pure Green
Industry
Eligibility
21 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Sterling Heights, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Jul 22, 2026, 2:13 PM EDT
Completed Not applicable Interventional Results available

Vagus Nerve Stimulation: Treatment for Gulf Veterans With Gulf War Illness

NCT02791893
View directory record Official record
Conditions
Pain, Migraine
Interventions
VNS device, Inactive device
Device
Lead sponsor
Benjamin Natelson
Other
Eligibility
42 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
East Orange, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced Jul 22, 2026, 2:13 PM EDT
Completed Phase 2 Interventional Results available

A Randomized Study Evaluating the Efficacy and Safety of Timolol Ophthalmic Solution as an Acute Treatment of Migraine

NCT03836664
View directory record Official record
Conditions
Migraine
Interventions
Timolol, Placebo
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Jul 22, 2026, 2:13 PM EDT
Completed Phase 2 Interventional

Mind and Body Approaches to Pain Reduction in Youth With Migraine

NCT03472092
View directory record Official record
Conditions
Headache, Migraine, Migraine, Migraine Disorders, Headache
Interventions
Cognitive Behavioral Therapy (CBT), Placebo, Amitriptyline, Biofeedback-Assisted Relaxation Training (BART), Cognitive Reappraisal Training (CR)
Behavioral · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years to 17 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Jul 22, 2026, 2:13 PM EDT
Completed Phase 3 Interventional Results available

A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura

NCT02614287
View directory record Official record
Conditions
Migraine
Interventions
Galcanezumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
13
States / cities
Santa Monica, California • Spring Valley, California • Stamford, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Jul 22, 2026, 2:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Sphenopalatine Ganglion Block Study

NCT05707754
View directory record Official record
Conditions
Sphenopalatine Ganglion Nerve Block
Interventions
Bupivacaine, angiocatheter
Drug · Device
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Jul 22, 2026, 2:13 PM EDT
Terminated No phase listed Observational

Treximet Migraine Brain Imaging Research Study

NCT01112553
View directory record Official record
Conditions
Acute Migraine
Interventions
Not listed
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Jul 22, 2026, 2:13 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Study in Participants With Acute Migraines Headaches

NCT00804973
View directory record Official record
Conditions
Migraine Headache
Interventions
LY2590443, Placebo injection, Sumatriptan, Placebo capsule
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
19
States / cities
Beverly Hills, California • Chula Vista, California • Fresno, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Jul 22, 2026, 2:13 PM EDT